These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 21129461)

  • 1. Proniosomes as a carrier system for transdermal delivery of tenoxicam.
    Ammar HO; Ghorab M; El-Nahhas SA; Higazy IM
    Int J Pharm; 2011 Feb; 405(1-2):142-52. PubMed ID: 21129461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nano-proniosomes enhancing the transdermal delivery of mefenamic acid.
    Wen MM; Farid RM; Kassem AA
    J Liposome Res; 2014 Dec; 24(4):280-9. PubMed ID: 24779560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formulation and evaluation of proniosomes containing lornoxicam.
    Madan JR; Ghuge NP; Dua K
    Drug Deliv Transl Res; 2016 Oct; 6(5):511-8. PubMed ID: 27255375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigating the potential of employing bilosomes as a novel vesicular carrier for transdermal delivery of tenoxicam.
    Al-Mahallawi AM; Abdelbary AA; Aburahma MH
    Int J Pharm; 2015 May; 485(1-2):329-40. PubMed ID: 25796122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proniosomal gel for transdermal delivery of lornoxicam: optimization using factorial design and in vivo evaluation in rats.
    Shah H; Nair AB; Shah J; Bharadia P; Al-Dhubiab BE
    Daru; 2019 Jun; 27(1):59-70. PubMed ID: 30701460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oro-dental mucoadhesive proniosomal gel formulation loaded with lornoxicam for management of dental pain.
    Abdelbary GA; Aburahma MH
    J Liposome Res; 2015; 25(2):107-21. PubMed ID: 25058447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formulation of Niosomal Gel for Enhanced Transdermal Lornoxicam Delivery: In-Vitro and In-Vivo Evaluation.
    El-Ridy MS; Yehia SA; Mohsen AM; El-Awdan SA; Darwish AB
    Curr Drug Deliv; 2018; 15(1):122-133. PubMed ID: 28240177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of proniosomes as an alternative strategy to optimize piroxicam transdermal delivery.
    Alsarra IA
    J Microencapsul; 2009 May; 26(3):272-8. PubMed ID: 18720197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel sugar esters proniosomes for transdermal delivery of vinpocetine: preclinical and clinical studies.
    El-Laithy HM; Shoukry O; Mahran LG
    Eur J Pharm Biopharm; 2011 Jan; 77(1):43-55. PubMed ID: 21056658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proniosomal formulation of curcumin having anti-inflammatory and anti-arthritic activity in different experimental animal models.
    Kumar K; Rai AK
    Pharmazie; 2012 Oct; 67(10):852-7. PubMed ID: 23136720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel non-ionic surfactant proniosomes for transdermal delivery of lacidipine: optimization using 2(3) factorial design and in vivo evaluation in rabbits.
    Soliman SM; Abdelmalak NS; El-Gazayerly ON; Abdelaziz N
    Drug Deliv; 2016 Jun; 23(5):1608-22. PubMed ID: 26758033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of nanostructured lipid carriers on transdermal delivery of tenoxicam in irradiated rats.
    Bawazeer S; El-Telbany DFA; Al-Sawahli MM; Zayed G; Keed AAA; Abdelaziz AE; Abdel-Naby DH
    Drug Deliv; 2020 Dec; 27(1):1218-1230. PubMed ID: 32772730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of novel transdermal self-adhesive films for tenoxicam, an anti-inflammatory drug.
    Nesseem DI; Eid SF; El-Houseny SS
    Life Sci; 2011 Sep; 89(13-14):430-8. PubMed ID: 21777594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transdermal Lipid Nanocarriers: A Potential Delivery System for Lornoxicam.
    Dasgupta S; Ray S; Dey S; Pal P; Mazumder B
    Pharm Nanotechnol; 2017; 5(1):32-43. PubMed ID: 28948909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formulation Optimization and In-vitro and In-vivo Evaluation of Lornoxicam Ethosomal Gels with Penetration Enhancers.
    Li K; Gao S; Tian B; Shi Y; Lv Q; Han J
    Curr Drug Deliv; 2018; 15(3):424-435. PubMed ID: 29219057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel vesicular transdermal delivery of nifedipine - preparation, characterization and in vitro/in-vivo evaluation.
    Yasam VR; Jakki SL; Natarajan J; Venkatachalam S; Kuppusamy G; Sood S; Jain K
    Drug Deliv; 2016; 23(2):619-30. PubMed ID: 25005581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formulation and evaluation of meloxicam niosomes as vesicular carriers for enhanced skin delivery.
    El-Menshawe SF; Hussein AK
    Pharm Dev Technol; 2013; 18(4):779-86. PubMed ID: 21913880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multivariate optimization of formulation variables influencing flurbiprofen proniosomes characteristics.
    Zidan AS; Mokhtar M
    J Pharm Sci; 2011 Jun; 100(6):2212-21. PubMed ID: 21259237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a nanogel formulation for transdermal delivery of tenoxicam: a pharmacokinetic-pharmacodynamic modeling approach for quantitative prediction of skin absorption.
    Elkomy MH; El Menshawe SF; Eid HM; Ali AM
    Drug Dev Ind Pharm; 2017 Apr; 43(4):531-544. PubMed ID: 27910712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic Development of Transethosomal Gel System of Piroxicam: Formulation Optimization, In Vitro Evaluation, and Ex Vivo Assessment.
    Garg V; Singh H; Bhatia A; Raza K; Singh SK; Singh B; Beg S
    AAPS PharmSciTech; 2017 Jan; 18(1):58-71. PubMed ID: 26868380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.